Dear Editor, Anaplastic large cell lymphoma, ALK positive is characterized by increased expression of the ALK protein.
Though two-thirds can be cured with chemotherapy, patients with refractory disease have limited options [1] . ALK has been successfully targeted by crizotinib in lung cancer and reports show success in ALK? lymphomas also [2] .
A 38-year female presented with right iliac fossa pain in June 2014. She had a large soft tissue mass in the right ilio-psoas region extending from the level of L1 to L5 vertebra with bony destruction of L3 vertebra (Fig. 1a, b) . Biopsy from the mass showed ALK? ALCL. She started CHOP chemotherapy but progressed after cycle 1. With a more intensive therapy (LMB-89, group B protocol), she initially responded, but again progressed after cycle 5. The lymphoma continued to progress on salvage DHAP chemotherapy. She developed intense pain in the iliolumbar region which was poorly controlled with morphine and resulted in spasm of the iliopsoas muscles and fixed flexion at right hip. She received radiation with partial relief of pain but remained bed bound in poor general condition. At this point, we started oral therapy with crizotinib 250 mg twice daily. Within 2 weeks, there was complete resolution of pain and patient was able to walk. Follow up CT scans showed progressive improvement and PET-CT scan done after 6 months of crizotinib showed complete metabolic response (Fig. 1c, d ). Patient was unwilling for stem cell transplant and hence crizotinib was continued. She has completed 30 months of crizotinib till now and remains in complete anatomic and metabolic response.
This report highlights a patient with chemo-refractory ALK? ALCL showing a dramatic and sustained response to ALK-targeted therapy. Complete response to crizotinib is not uncommon in ALKL? ALCL [2, 3] .
The fusion protein NPM-ALK promotes tumorigencity by binding to and constitutively activating a host of cellular signalling proteins, including those in the signalling pathways of signal transducer and activator of transcription 3 (STAT3), MEK/ERK, mammalian target of rapamycin (mTOR) and phosphoinositide 3 kinase (PI3K)/Akt leading to cell proliferation and resistance to apoptosis. Crizotinib exerts its therapeutic effect by inhibiting the phosphorylation of the ALK tyrosine kinase and thus blocks the downstream effects of this oncogene [4] . The duration of therapy is currently unclear and the longest duration of reported in literature is 37 months [5] . Though crizotinib may be considered as a reasonable option in patients with chemo refractory ALK? ALCL, this particular case represents an exceptional response. Further studies are needed to establish more long term data regarding efficacy and safety.
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